Dejan Maglic

1.5k total citations
14 papers, 640 citations indexed

About

Dejan Maglic is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Dejan Maglic has authored 14 papers receiving a total of 640 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 9 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Dejan Maglic's work include Cancer-related Molecular Pathways (8 papers), RNA modifications and cancer (3 papers) and Epigenetics and DNA Methylation (3 papers). Dejan Maglic is often cited by papers focused on Cancer-related Molecular Pathways (8 papers), RNA modifications and cancer (3 papers) and Epigenetics and DNA Methylation (3 papers). Dejan Maglic collaborates with scholars based in United States, Italy and United Kingdom. Dejan Maglic's co-authors include Kazushi Inoue, Robert D. Kendig, Pankaj Taneja, Fumitake Kai, Sinan Zhu, Donna P. Frazier, Takayuki Sugiyama, Michael T. Dill, Fernando D. Camargo and Raffaele Calogero and has published in prestigious journals such as The EMBO Journal, PLoS ONE and Cancer Research.

In The Last Decade

Dejan Maglic

14 papers receiving 629 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dejan Maglic United States	13	387	328	141	125	62	14	640
Jonathan E. Grim United States	8	408 1.1×	201 0.6×	85 0.6×	95 0.8×	42 0.7×	14	528
Rinat Keren United States	5	532 1.4×	327 1.0×	160 1.1×	141 1.1×	63 1.0×	5	763
Renata Kusińska Poland	14	256 0.7×	248 0.8×	166 1.2×	80 0.6×	45 0.7×	25	550
Verónica Calvo United States	9	265 0.7×	218 0.7×	167 1.2×	98 0.8×	51 0.8×	13	513
Elaine McSherry Ireland	7	314 0.8×	203 0.6×	118 0.8×	95 0.8×	35 0.6×	8	530
Sylvie André Switzerland	5	386 1.0×	393 1.2×	248 1.8×	55 0.4×	63 1.0×	7	689
Jarrod R. Tremayne United States	8	310 0.8×	264 0.8×	75 0.5×	60 0.5×	60 1.0×	13	491
Fabiana Lüönd Switzerland	7	380 1.0×	330 1.0×	237 1.7×	75 0.6×	95 1.5×	9	683
Montserrat Arumí-Uría Spain	9	252 0.7×	235 0.7×	101 0.7×	135 1.1×	82 1.3×	13	498
Dragana Kopanja United States	16	624 1.6×	230 0.7×	136 1.0×	66 0.5×	48 0.8×	20	739

Countries citing papers authored by Dejan Maglic

Since Specialization

Citations

This map shows the geographic impact of Dejan Maglic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dejan Maglic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dejan Maglic more than expected).

Fields of papers citing papers by Dejan Maglic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dejan Maglic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dejan Maglic. The network helps show where Dejan Maglic may publish in the future.

Co-authorship network of co-authors of Dejan Maglic

This figure shows the co-authorship network connecting the top 25 collaborators of Dejan Maglic. A scholar is included among the top collaborators of Dejan Maglic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dejan Maglic. Dejan Maglic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Casaletto, Jessica B., Dejan Maglic, B. Barry Touré, et al.. (2021). Abstract 1455: RLY-4008, a novel precision therapy for FGFR2-driven cancers designed to potently and selectively inhibit FGFR2 and FGFR2 resistance mutations. Cancer Research. 81(13_Supplement). 1455–1455. 13 indexed citations

Cheung, Priscilla, Michael T. Dill, Wei-Chien Yuan, et al.. (2020). Regenerative Reprogramming of the Intestinal Stem Cell State via Hippo Signaling Suppresses Metastatic Colorectal Cancer. Cell stem cell. 27(4). 590–604.e9. 125 indexed citations

Maglic, Dejan, Karin Schlegelmilch, Antonella F. M. Dost, et al.. (2018). YAP‐TEAD signaling promotes basal cell carcinoma development via a c‐JUN/AP1 axis. The EMBO Journal. 37(17). 49 indexed citations

Maglic, Dejan, Daniel B. Stovall, J. Mark Cline, et al.. (2014). DMP1β, a splice isoform of the tumour suppressor DMP1 locus, induces proliferation and progression of breast cancer. The Journal of Pathology. 236(1). 90–102. 33 indexed citations

Fry, Elizabeth A., Pankaj Taneja, Dejan Maglic, et al.. (2013). Dmp1α Inhibits HER2/neu-Induced Mammary Tumorigenesis. PLoS ONE. 8(10). e77870–e77870. 22 indexed citations

Stovall, Daniel B., Meimei Wan, Lance D. Miller, et al.. (2013). The Regulation of SOX7 and Its Tumor Suppressive Role in Breast Cancer. American Journal Of Pathology. 183(5). 1645–1653. 51 indexed citations

Frazier, Donna P., Robert D. Kendig, Fumitake Kai, et al.. (2012). Dmp1 Physically Interacts with p53 and Positively Regulates p53′s Stability, Nuclear Localization, and Function. Cancer Research. 72(7). 1740–1750. 34 indexed citations

Maglic, Dejan, Elizabeth A. Fry, Pankaj Taneja, et al.. (2012). Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer. Oncogene. 32(35). 4120–4129. 30 indexed citations

Taneja, Pankaj, et al.. (2011). Transgenic and Knockout Mice Models to Reveal the Functions of Tumor Suppressor Genes. Clinical Medicine Insights Oncology. 5. 235–57. 35 indexed citations

10.

Maglic, Dejan, et al.. (2011). Abstract 3076: MEKK1 is a novel modulator of the Arf-p53 pathway via Dmp1 phosphorylation. Cancer Research. 71(8_Supplement). 3076–3076. 1 indexed citations

11.

Taneja, Pankaj, Dejan Maglic, Fumitake Kai, et al.. (2010). Critical Roles of DMP1 in Human Epidermal Growth Factor Receptor 2/neu-Arf-p53 Signaling and Breast Cancer Development. Cancer Research. 70(22). 9084–9094. 33 indexed citations

12.

Taneja, Pankaj, Dejan Maglic, Fumitake Kai, et al.. (2010). Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Clinical Medicine Insights Oncology. 4. 15–34. 125 indexed citations

13.

Taneja, Pankaj, Donna P. Frazier, Robert D. Kendig, et al.. (2009). MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Review of Molecular Diagnostics. 9(5). 423–440. 56 indexed citations

14.

Mallakin, Ali, Takayuki Sugiyama, Fumitake Kai, et al.. (2009). The Arf‐inducing transcription factor Dmp1 encodes a transcriptional activator of amphiregulin, thrombospondin‐1, JunB and Egr1. International Journal of Cancer. 126(6). 1403–1416. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact